215 related articles for article (PubMed ID: 16960814)
1. A deleterious mutation in SAMD9 causes normophosphatemic familial tumoral calcinosis.
Topaz O; Indelman M; Chefetz I; Geiger D; Metzker A; Altschuler Y; Choder M; Bercovich D; Uitto J; Bergman R; Richard G; Sprecher E
Am J Hum Genet; 2006 Oct; 79(4):759-64. PubMed ID: 16960814
[TBL] [Abstract][Full Text] [Related]
2. Normophosphatemic familial tumoral calcinosis is caused by deleterious mutations in SAMD9, encoding a TNF-alpha responsive protein.
Chefetz I; Ben Amitai D; Browning S; Skorecki K; Adir N; Thomas MG; Kogleck L; Topaz O; Indelman M; Uitto J; Richard G; Bradman N; Sprecher E
J Invest Dermatol; 2008 Jun; 128(6):1423-9. PubMed ID: 18094730
[TBL] [Abstract][Full Text] [Related]
3. A novel homozygous missense mutation in FGF23 causes Familial Tumoral Calcinosis associated with disseminated visceral calcification.
Chefetz I; Heller R; Galli-Tsinopoulou A; Richard G; Wollnik B; Indelman M; Koerber F; Topaz O; Bergman R; Sprecher E; Schoenau E
Hum Genet; 2005 Nov; 118(2):261-6. PubMed ID: 16151858
[TBL] [Abstract][Full Text] [Related]
4. Familial tumoral calcinosis: from characterization of a rare phenotype to the pathogenesis of ectopic calcification.
Sprecher E
J Invest Dermatol; 2010 Mar; 130(3):652-60. PubMed ID: 19865099
[TBL] [Abstract][Full Text] [Related]
5. Functional characterization of SAMD9, a protein deficient in normophosphatemic familial tumoral calcinosis.
Hershkovitz D; Gross Y; Nahum S; Yehezkel S; Sarig O; Uitto J; Sprecher E
J Invest Dermatol; 2011 Mar; 131(3):662-9. PubMed ID: 21160498
[TBL] [Abstract][Full Text] [Related]
6. Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders.
Frishberg Y; Topaz O; Bergman R; Behar D; Fisher D; Gordon D; Richard G; Sprecher E
J Mol Med (Berl); 2005 Jan; 83(1):33-8. PubMed ID: 15599692
[TBL] [Abstract][Full Text] [Related]
7. Long-term clinical outcome and phenotypic variability in hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome caused by a novel GALNT3 mutation; case report and review of the literature.
Rafaelsen S; Johansson S; Ræder H; Bjerknes R
BMC Genet; 2014 Sep; 15():98. PubMed ID: 25249269
[TBL] [Abstract][Full Text] [Related]
8. Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature.
Chakhtoura M; Ramnitz MS; Khoury N; Nemer G; Shabb N; Abchee A; Berberi A; Hourani M; Collins M; Ichikawa S; El Hajj Fuleihan G
Osteoporos Int; 2018 Sep; 29(9):1987-2009. PubMed ID: 29923062
[TBL] [Abstract][Full Text] [Related]
9. Familial tumoral calcinosis and testicular microlithiasis associated with a new mutation of GALNT3 in a white family.
Campagnoli MF; Pucci A; Garelli E; Carando A; Defilippi C; Lala R; Ingrosso G; Dianzani I; Forni M; Ramenghi U
J Clin Pathol; 2006 Apr; 59(4):440-2. PubMed ID: 16567474
[TBL] [Abstract][Full Text] [Related]
10. Hyperphosphatemic familial tumoral calcinosis caused by a mutation in GALNT3 in a European kindred.
Specktor P; Cooper JG; Indelman M; Sprecher E
J Hum Genet; 2006; 51(5):487-490. PubMed ID: 16528452
[TBL] [Abstract][Full Text] [Related]
11. [SAMD9 mutation in normophosphatemic familial tumoral calcinosis].
Dereure O
Ann Dermatol Venereol; 2007 May; 134(5 Pt 1):505. PubMed ID: 17507861
[No Abstract] [Full Text] [Related]
12. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis.
Topaz O; Shurman DL; Bergman R; Indelman M; Ratajczak P; Mizrachi M; Khamaysi Z; Behar D; Petronius D; Friedman V; Zelikovic I; Raimer S; Metzker A; Richard G; Sprecher E
Nat Genet; 2004 Jun; 36(6):579-81. PubMed ID: 15133511
[TBL] [Abstract][Full Text] [Related]
13. Mouse Samd9l is not a functional paralogue of the human SAMD9, the gene mutated in normophosphataemic familial tumoral calcinosis.
Li Q; Guo H; Matsui H; Honda H; Inaba T; Sundberg JP; Sprecher E; Uitto J
Exp Dermatol; 2012 Jul; 21(7):554-6. PubMed ID: 22716256
[TBL] [Abstract][Full Text] [Related]
14. Hyperphosphatemic Familial Tumoral Calcinosis in Two Siblings with a Novel Mutation in
Kışla Ekinci RM; Gürbüz F; Balcı S; Bişgin A; Taştan M; Yüksel B; Yılmaz M
J Clin Res Pediatr Endocrinol; 2019 Feb; 11(1):94-99. PubMed ID: 30015621
[TBL] [Abstract][Full Text] [Related]
15. Hyperphosphatemic familial tumoral calcinosis caused by a novel variant in the GALNT3 gene.
Mahjoubi F; Ghadir M; Samanian S; Heydari I; Honardoost M
J Endocrinol Invest; 2020 Aug; 43(8):1125-1130. PubMed ID: 32125652
[TBL] [Abstract][Full Text] [Related]
16. Clinical and genetic analysis of idiopathic normophosphatemic tumoral calcinosis in 19 patients.
Zuo QY; Cao X; Liu BY; Yan D; Xin Z; Niu XH; Li C; Deng W; Dong ZY; Yang JK
J Endocrinol Invest; 2020 Feb; 43(2):173-183. PubMed ID: 31535357
[TBL] [Abstract][Full Text] [Related]
17. GALNT3, a gene associated with hyperphosphatemic familial tumoral calcinosis, is transcriptionally regulated by extracellular phosphate and modulates matrix metalloproteinase activity.
Chefetz I; Kohno K; Izumi H; Uitto J; Richard G; Sprecher E
Biochim Biophys Acta; 2009 Jan; 1792(1):61-7. PubMed ID: 18976705
[TBL] [Abstract][Full Text] [Related]
18. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia.
Benet-Pagès A; Orlik P; Strom TM; Lorenz-Depiereux B
Hum Mol Genet; 2005 Feb; 14(3):385-90. PubMed ID: 15590700
[TBL] [Abstract][Full Text] [Related]
19. A novel
Zuo Q; Yang W; Liu B; Yan D; Wang Z; Wang H; Deng W; Cao X; Yang J
Front Endocrinol (Lausanne); 2022; 13():1008800. PubMed ID: 36213261
[TBL] [Abstract][Full Text] [Related]
20. Absence of intraepidermal glycosyltransferase ppGalNac-T3 expression in familial tumoral calcinosis.
Topaz O; Bergman R; Mandel U; Maor G; Goldberg R; Richard G; Sprecher E
Am J Dermatopathol; 2005 Jun; 27(3):211-5. PubMed ID: 15900124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
